Absolute n | Percentage % | |
---|---|---|
Age years | ||
< 60 years | 20 | 43.4 |
≥ 60 years | 26 | 56.6 |
Gender | ||
Female | 12 | 26.1 |
Male | 34 | 73.9 |
Histology | ||
Adenocarcinoma | 12 | 26.1 |
Squamous-cell carcinoma | 33 | 71.7 |
Non other specified | 1 | 2.2 |
TNM-stage disease | ||
T4 N0 M0 | 34 | 73.9 |
T4 N1 M0 | 12 | 26.1 |
Clinical performance status | Absolute n | Percentage % |
---|---|---|
ECOG-Status | ||
ECOG 0 | 27 | 58.7 |
ECOG 1 | 18 | 39.1 |
ECOG 2 | 1 | 2.2 |
NYHA-Class | ||
No cardiac insufficiency | 32 | 69.6 |
NYHA 1 | 10 | 21.7 |
NYHA 2 | 4 | 8.7 |
COPD-Score (GOLD) | ||
No pulmonary obstruction | 17 | 36.9 |
COPD 1 | 5 | 10.9 |
COPD 2 | 20 | 43.5 |
COPD 3 | 3 | 6.5 |
COPD 4 | 1 | 2.2 |
Absolute n | Percentage % | |
---|---|---|
Operable | 17 | 36.9 |
Functional non-operable | 25 | 54.4 |
Technical non-operable | 4 | 8.7 |
Total | 46 pts | 100% |
Tumor characteristics | Mean | Range |
---|---|---|
Grading | 2.5 | 1–4 |
PD-L1 [%] | 27.25 [12 pts tested] | 0–100 |
Post-CTx MTV | 61.7 [29 pts] | 0.2–265.2 |
SUVmax | 4.1 | 2.0–13.8 |